Favorable immune signature in CLL patients, defined by antigen-specific T-cell responses, might prevent second skin cancers

Juliane Sarah WalzDepartment of Hematology and Oncology, University of Tübingen, Tübingen, Germany; Correspondence[email protected]
View further author information

Daniel Johannes KowalewskiDepartment of Immunology, Institute for Cell Biology, University of Tübingen, Tübingen, Germany; View further author information

Linus BackertDepartment of Immunology, Institute for Cell Biology, University of Tübingen, Tübingen, Germany; ;Applied Bioinformatics, Center for Bioinformatics and Department of Computer Science, University of Tübingen, Tübingen, Germany; View further author information

Annika NeldeDepartment of Hematology and Oncology, University of Tübingen, Tübingen, Germany; ;Department of Immunology, Institute for Cell Biology, University of Tübingen, Tübingen, Germany; View further author information

Oliver KohlbacherApplied Bioinformatics, Center for Bioinformatics and Department of Computer Science, University of Tübingen, Tübingen, Germany; ;Quantitative Biology Center, University of Tübingen, Tübingen, Germany; ;Biomolecular Interactions, Max Planck Institute for Developmental Biology, Tübingen, Germany; View further author information

Benjamin WeideDepartment of Dermatology, University Hospital Tübingen, Tübingen, Germany; View further author information

Lothar KanzDepartment of Hematology and Oncology, University of Tübingen, Tübingen, Germany; View further author information

Helmut Rainer SalihDepartment of Hematology and Oncology, University of Tübingen, Tübingen, Germany; ;Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Partner Site Tübingen, Tübingen, Germany; View further author information

Hans-Georg RammenseeDepartment of Immunology, Institute for Cell Biology, University of Tübingen, Tübingen, Germany; ;German Cancer Consortium (DKTK), DKFZ Partner Site Tübingen, Tübingen, GermanyView further author information

Stefan StevanovićDepartment of Immunology, Institute for Cell Biology, University of Tübingen, Tübingen, Germany; ;German Cancer Consortium (DKTK), DKFZ Partner Site Tübingen, Tübingen, GermanyView further author information

show all

Favorable immune signature in CLL patients, defined by antigen-specific T-cell responses, might prevent second skin cancers

ICMJE Forms for Disclosure of Potential Conflicts of Interest

Supplementary Table S1

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Favorable immune signature in CLL patients, defined by antigen-specific T-cell responses, might prevent second skin cancers

ICMJE Forms for Disclosure of Potential Conflicts of Interest

Supplementary Table S1

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date